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Abstract 
Advancement in sequencing technology enables the study of association between complex 
disorders and rare variants with low minor allele frequencies. One of the major challenges in rare 
variant testing is lack of statistical power of traditional testing methods due to extremely low 
variances of single nucleotide polymorphisms. In this paper, we introduce a W-test collapsing 
method that evaluates the distributional differences in cases and controls using a combined log of 
odds ratio. The proposed method is compared with the Weighted-Sum Statistic and Sequence 
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Kernel Association Test using simulation data sets and showed better performances and faster 
computing speed. In the study of real next generation sequencing data set of hypertensive disorder, 
we identified genes of interesting biological functions that are associated to metabolism disorder 
and inflammation, which include the MACROD1, NLRP7, AGK, PAK6 and APBB1. The W-test 
collapsing method offers a fast, effective and alternative way for rare variants association analysis.  
 
Background 
In the past decade, genetic association studies identified a repertoire of associated variants for 
complex disorders [1]. However, a large portion of the disease heritability remains unexplained. 
Areas that may account for the missing heritability in complex traits include polygenetic effects, 
gene-environment interactions, and rare variants associations [2]. Sequencing technology 
development in recent years allow deep DNA sequencing to be done at lower cost, and the Next 
Generation Sequencing (NGS) is made available for studying extreme low frequency variants. One 
main challenge in studying rare variants association is the lack of statistical power due to low 
minor allele frequency (MAF). Furthermore, the high volume of genetic markers also increases 
the burden of multiple testing. A number of statistical methods for rare variant association testing 
have been proposed, which can be generally divided into two categories, the burden tests such as 
the Weighted Sum Statistic (WSS) [3] and Combined Multivariate Collapsing [4]; and the variance 
component tests such as the C-alpha test [5] and the Sequence Kernel Association Test (SKAT) 
[6]. Both types of methods increase power for rare variants by defining larger genomic regions to 
conduct the test. In this paper, we introduce a W-test collapsing method to evaluate rare variant 
data. The method tests the distributional differences in cases and controls using a retrospective 
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design after collapsing the allele frequencies within a genomic region。 The test statistic carries 
an inherent Chi-squared distribution with data-set dependent degrees of freedom. Power and type 
I error rate of W-test collapsing is compared with the WSS and the SKAT using simulated data 
sets. The proposed method showed better performances and several hundred times faster in 
computing speed. The proposed method is also applied on real NGS data set of hypertensive 
disorder, and interesting genes have been found.  
Method 
The W-test 
The W-test is formulated to test the distributional difference of a SNP in the affected from the 
unaffected group [7]. Suppose a variant X has k levels, and Y is binary. If a variant carries three 
genotypes, AA, Aa and aa, then k=3. The test takes the following form:  
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where is the proportion of cases in cell-i out of total case number, and  is the proportion of 
controls in cell-i out of total control number. SEi is the standard error of log odds ratio of cell-i, in 
which n1i and n0i are the number of cases and controls in the ith cell; N1 and N0 are the total number 
of cases and controls, respectively.  The scalar h and the degrees of freedom parameter f are 
obtained by estimating the covariance matrix from the bootstrapped data under null hypothesis. 
The statistic follows a Chi-squared distribution with f degrees of freedom.  Empirical studies give 
h ≈ (k-1)/k and f ≈ k-1. When sample size and the number of markers are both around 1000, the 
ip1ˆ ip1ˆ
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estimated parameters begin to converge at bootstrap times greater than 200 [7]. The h and f of 
simulation and real data set can be found in Supplementary Materials S1. The W-test is especially 
powerful under low frequency variable environment (when MAF is between 1-5%) [7], as the 
data-dependent parameters help to reduce bias in test probability distribution arise from small 
MAFs.   
The W-test collapsing method 
The W-test collapsing method is a direct extension of the original W-test on rare variants. Suppose 
a genomic region contains m rare SNPs; each SNP can form a contingency table. The m 
contingency tables of the SNPs in the genomic region are summed cell by cell, and a combined 
contingency table is formed for this collapsing region. The W-test collapsing applies the original 
W-test on top of the combined contingency table as a new statistic, which follows a Chi-squared 
distribution with f degrees of freedom. The h and f are estimated from the data under the null 
hypothesis based on the collapsed region.   
 
Comparison with other rare variant methods  
Two representative rare variant methods are considered as alternative approaches, namely, the 
SKAT and the WSS [3, 6]. The SKAT is a kernel machine regression method that incorporates a 
variance component score for coefficient evaluation.  It has the advantage of dealing with both 
continuous and discrete phenotypes, and can test genetic effect in opposite directions [8]. The WSS 
first gives each individual a weighted sum score of mutations counts, and then test for excess of 
mutations in cases compared to null hypothesis [9]. Permutations are needed to calculate p-values 
for the WSS.  
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Simulation data  
Simulation data are used to evaluate power and type I error rate of different methods. Each 
replicate includes 1,920 rare SNPs and 2,000 subjects. Rare variants are randomly generated to 
have MAF range between 0.01% and 1%. One gene is consisted of 32 SNPs. Each replication data 
includes 60 genes, in which 10 genes contain causal SNPs. The phenotypes are generated by a 
logistic regression model containing all the causal SNPs and a random error term [10]. Two 
phenotypic models are considered:  
Scenario I:  In a causal gene, 12 causal SNPs cluster together in the same effect direction; 
Scenario II: In a causal gene, 8 causal SNPs cluster together in opposite effect directions, with 
6 SNPs of risk effect and 2 SNPs of protective effect.  
There are 37.5% of causal variants in Scenario I, and 25% in Scenario II. It is known that Scenario 
I model favors burden-like test, and scenario II is suitable to apply the variance component test 
[11]. Five hundred replicated data sets are generated to calculate the power and type I error rate. 
Power is the averaged true positive rates in 500 replicates, and type I error rate is the average false 
positive rates. A positive gene is defined as the gene which p-value is smaller than Bonferroni 
corrected alpha of 5% in 60 genes.   
 
GAW18 simulated and real data sets 
Both simulated and real data set from the Genetic Analysis Workshop 18 (GAW18) are applied.  
The subjects are unrelated Mexican Americans who are enriched in type 2 diabetes, drawn from 
the T2D-GENES consortium project 2 [10]. The GAW18 simulated data sets contain real genotype 
data and predefined systolic and diastolic blood pressure (SBP and DBP) generated from a linear 
regression model [10]. Hypertension is defined at SBP>90 mm Hg or DBP>140 mm Hg. We use 
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rare variants (MAF<1%) on chromosome 3 and 200 replicates for power and type I error rate 
calculation. The simulated data sets consist of 330 cases, 1600 controls and 42,825 rare SNPs.  The 
total number of causal SNPs is 164.  The rare variant methods need to be applied based on a certain 
genomic region, while the optimal regions are non-identical for different methods. We estimate 
optimal collapsing window for each method at which they have the best power for the GAW18 
simulated dataset. The optimal window for the SKAT and the W-test is 15 SNPs, and for WSS is 
10 SNPs. A causal region is defined as the genomic area containing at least one causal SNP. 
Receiver operating characteristic (ROC) curve is plotted using the top number of collapsed regions. 
For real data analysis, there are 398 hypertensive individuals and 1,453 controls. Quality control 
(QC) is conducted to remove variants with missing value percentage over 5% and inconsistent 
genotyping format. Odd numbered chromosomes are evaluated and the total number of rare SNPs 
passed QC is 308,722 in the real data set. The collapsing window size for real data is 15, so the 
number of multiple tests is 308,722/15=25,385, and Bonferroni corrected significance level at 5% 
alpha is 1.97×10-6.  
Results  
Comparison of alternative methods in simulation data  
In Scenario I where causal SNPs in a gene have the same effect direction, the W-test’s power is 
66.6%, slightly better than WSS’s 66.3%. Both burden tests outperform the SKAT’s power 55.9% 
(Table 1).  For Scenario II, where the causal markers show different effect directions, the SKAT’s 
power is the highest, 93.0%, followed by W-test’s 47.1%, and WSS’s 39.6%.  All methods’ type 
I error rates are conservative: 0.13% for W-test, 0.13% for SKAT, and 0.17% for WSS (Table 1). 
The W outperforms WSS in both scenarios. Furthermore, the W-test takes 0.06 seconds to evaluate 
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10 genes; it is 235 times faster than SKAT, and 393 times faster than the WSS. The W-test benefits 
from its intrinsic probability distribution estimated from the small bootstrapped samples to 
calculate p-values, compared to other rare variant association tests that require complete 
permutation or Monte Carlo estimation.  
Application to GAW18 simulation study  
The ROC curves of the W-test, SKAT and the WSS are plotted in Figure 1. The figure shows that 
in the GAW18 data set, all methods have low power and high false positive rates. Similar lack of 
power has been observed by other studies on the same data [11-13]. Nevertheless, the W-test 
performs the best among the three methods. At false positive rate 52.5%, the W-test collapsing has 
true positive rate (TPR) 57.3%, which is 52% for the SKAT and 52.8% for the WSS. The causal 
SNPs distribution in the top ranked causal genes is exhibited in Table 2. All methods are able to 
find extreme rare variants with MAF 0.0003 and SNPs of very small effect sizes. The 
characteristics of identified causal markers are also intriguing: Except for one gene ZBTB38 that 
is identified by all three methods, the regions short-listed by SKAT and WSS share no similarities, 
while the W-test found common regions to the other two methods (Table 2). The causal regions 
identified by SKAT are mostly composed of a single SNP with very large effect sizes (coefficients 
with absolute value ranges from 0.06 to 20); and the WSS identified regions containing two or 
more causal SNPs of moderate effect size (coefficients in the linear regression with absolute 
magnitude under 1.5).  Interestingly, the W-test collapsing identified both the moderate effect sizes 
genes SEMA3F and MUC13, and the unique genes SENP5 of a large effect size. These results 
showed that the W-test collapsing has slight power advantage than the SKAT and WSS in the 
GAW18 data; it also shares common properties of the other two distinct methods, and has unique 
finding of its own.  
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Application to real hypertension exome sequencing data 
We applied the W-test collpasing method on real exome data of hypertensive disorder. One region 
reached bonferroni corrected significance level with p value 6.1×10-7. Not surprisingly, SNPs in 
this region are not discoverable by single marker test as they are individually non-significant. The 
identified chromosome position contains the gene MACROD1/LRP16 (11q11, average MAF = 
0.001, odds ratio for collapsed marker = 3.84), which is a ubiquitous protein module that binds 
ADP-ribose derivatives, and supports many different protein functions and pathways. It was 
reported that the LRP16 is over expressed in tissues of colorectal and gastric carcinoma patients 
[14, 15]. The top 17 regions that have large to moderate effect are listed in Table 3.  These include 
genes NLRP7, AGK, PAK6 and APBB1, which have potential association to hypertension. The 
NLRP7 (MAF = 0.0027, OR=2.23, W-test collapsing p-value = 8.3×10-6) encodes a protein that is 
implicated in the activation of proinflammatory caspases through multiprotein complexes 
inflammasones. Studies reported that this gene is associated with molar pregnancy and other 
pregnancy complications [16, 17]. The acylglycero kinase (AGK) is involved in lipid and 
glycerolipid metabolism, and it was found to have a significant over expression in retinas of 
diabetic rats [18], and may play a role in the development of cataract [19].  The gene PAK6 is a 
p21-activated kinase that is central to signal transduction and cellular regulation. Previous cell-
line, tissue and gene expression studies reported this gene may play essential roles in the initiation 
and progression of hepatocellular carcinoma [20, 21]. The protein encoded by APBB1 is a member 
of the Fe65 protein family, and interacts with the transcription factor LBP1 and the low-density 
lipoprotein receptor-related protein [22].  
Discussion  
 9 
 
We propose a W-test collapsing method to test the association between a dichotomous phenotype 
and rare genetic variants. It is model-free, fast, and tests the distributional differences in cases and 
controls through the integrated log odds ratios. Because of the odds ratio design, it has a unique 
retrospective design that is suitable to be applied on both prospective and retrospective data sets. 
The proposed method can be categorized as a burden test; therefore, it is more advantages under 
the scenario when the SNPs effect directions are the same, compared to variance component test. 
It outperforms another burden test WSS under different effect scenarios. The advantage of the 
proposed method, apart from power and controlled type I error rate, is its p-value calculation free 
from large permutation. There are two major beneficial aspects: first is the extraordinary 
computing speed. Almost all rare variant tests heavily rely on Monte Carlo or permutations to 
calculate p-values. And the computing burden prohibits possible optimization of collapsing region 
in whole exome sequencing data. Second, the test inherits a dataset-dependent probability 
distribution. The proposed method uses small bootstrapped samples under null hypothesis to 
estimate refined degrees of freedom (non-integer) for the testing probability distribution. Because 
the estimation involves data covariance structure, the resulting chi-squared distribution can 
corrects for potential bias due to complex data structures and can give accurate p-value calculation 
at minimum computing cost.  
 
We compared different methods at their optimized collapsing region on the GAW18 data set, 
which is usually not performed in the literature. The optimal bin size is related to the number of 
causal markers in the region, causal marker’s effect sizes and directions, weighting scheme and 
the distribution of mutations in cases and controls. This study demonstrated that the optimal 
window sizes are not the same for different methods; and the best collapsing bin is smaller than 
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the commonly adopted range, such as a gene or pathway [3, 6].  Further study is needed to explore 
how to locate the best collapsing region in real exome sequencing data.  
 
In terms of identified causal regions in GAW18 data, the W-test collapsing method shared 
similarities with the WSS that they both identified the regions populated with many causal variants. 
However, there are differences in the two burden methods: the WSS mainly found variants with 
moderate effect size, but the W-test collapsing identified large negative effect variants as well. The 
reason can be explained from the formulation of the two statistics. The WSS adds the number of 
mutated alleles in a genomic region and weight them inversely by the proportion of mutations in 
the unaffected subjects.  A critical assumption of the WSS is that the minor alleles are mutations 
and contribute to disease risk [3]; therefore, if the minor allele with protective effect are 
concentrated in the unaffected, the WSS will down weight the variants and could miss them. As a 
result, the causal gene SENP5 that contains 5 large negative effects SNPs is not short-listed by the 
WSS in the GAW18 simulation study, in which most of the mutations in this gene occur in the 
unaffected only once (Table 2).  On the contrary, the W-test collapsing does not make assumption 
on mutation effect; it directly tests the distributional differences between the affected and 
unaffected; therefore, it is more general than the WSS to identify protective effect rare variants. 
The SKAT performs a kernel regression using variance component in each region, and variants 
with small MAF will be given heavier weights. The SKAT method tends to select a region that 
includes a few rare variants with large effect sizes, and it allows variants within a region to adopt 
opposite effect directions. In the GAW18 simulation study, four out of the five top regions 
identified by SKAT contain only 1 causal marker, and the rest gene ARHGEF3 contains 2 SNPs 
of same effect direction. Except for the first gene, the SKAT does not share common identified 
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regions to the WSS and the W-test collapsing method.  The rest variation in the causal marker 
distribution relates to the noise SNPs contained in collapsing region, and the random variations in 
the replication data sets. The simulation study showed that the proposed method has advantage in 
locating clustered causal rare variants, and is more general than the WSS to detect protective 
variants. Nevertheless, the three tests discussed in this study all have distinct properties and 
strength. In real data analysis, when the underlying genetic model is unknown, the methods may 
need to be considered jointly to obtain a complete picture. There are existing combined test such 
as the SKAT-O and Fisher’s method, which pool the individual tests by some tuning parameters 
[23, 24]. These tests are more appropriate when the underlying model is unknown, but less 
powerful for specific scenarios [25]. The W-test collapsing method can be naturally pooled with 
the SKAT by the Fisher’s method, which we might explore in future study.  
To conclude, we proposed a W-test collapsing method to evaluate rare variant in exome 
sequencing data, thus enables the testing of the whole genome data under an integrated statistical 
framework. The proposed method offers a very efficient and effective way for rare variant 
association analysis.  
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Figure Legends 
Figure 1. ROC of Alternative Methods in GAW18 Simulation Data 
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Tables 
Table 1.  Power and type I error rates of rare variant association tests 
 
Statistical tests 
Power 
Scenario I1 
Power 
Scenario II2 
Type I error 
rate 
Speed3 
(seconds) 
WSS 66.3% 39.6% 0.17% 23.59 
SKAT 55.9% 93.0% 0.13% 14.13 
W-test 66.6% 47.1% 0.13% 0.06 
1 Scenario I: causal SNPs clustered together with the same effect direction 
2 Scenario II: causal SNPs clustered together, with opposite effect directions 
3 Speed is the averaged elapsed time of evaluating 10 genes  
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Table 2. Characteristics of identified markers by alternative methods in simulated dataset 
Method Rank Gene Number of Causal SNPs 
Causal SNPs in the gene 
position MAF SBP effect DBP effect 
SKAT 
1 ZBTB38 1 141164276 0.0003 -0.007 -0.002 
2 ARHGEF3 2 
56835799 
56835795 
0.0003 
0.0008 
-0.067 
-0.059 
-0.062 
-0.055 
3 MAP4 1 48040284 0.0003 -20.808 -9.682 
4 FLNB 1 58134409 0.0005 1.687 0.249 
5 MUC13 1 124646631 0.0003 0 -2.178 
WSS 
1 ZBTB38 1 141164276 0.0003 -0.007 -0.002 
2 SEMA3F 3 
50222143 
50214207 
50222178 
0.0008 
0.0005 
0.0010 
0.706 
0.00002 
0.00007 
0.505 
0.00001 
0.00005 
3 SEMA3F 3 
50222879 
50223334 
50223764 
0.0010 
0.0003 
0.0010 
1.361 
1.010 
1.101 
0.973 
0.722 
0.787 
4 MLH1 2 37048495 37045960 
0.0005 
0.0008 
0 
0 
-0.454 
-0.280 
5 MLH1 2 37061893 37061929 
0.0003 
0.0005 
0 
0 
-0.00004 
-0.00001 
W-test 
1 ZBTB38 1 141164276 0.0003 -0.007 -0.002 
2 SEMA3F 3 
50222879 
50223334 
50223764 
0.0010 
0.0003 
0.0010 
1.361 
1.010 
1.101 
0.973 
0.722 
0.787 
3 MUC13 2 124632448 124639097 
0.0005 
0.0008 
0 
0 
-1.244 
-0.476 
4 SENP5 5 
196612750 
196612959 
196613022 
196613096 
196613191 
0.0003 
0.0062 
0.0003 
0.0003 
0.0008 
-4.336 
-3.169 
-1.697 
-4.271 
-0.635 
0 
0 
0 
0 
0 
5 SEMA3F 4 
50225153 
50225255 
50225285 
50225454 
0.0003 
0.0003 
0.0003 
0.0003 
1.418 
0.00003 
1.391 
0.254 
1.013 
0.00002 
0.994 
0.182 
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Table 3. Top associated regions in real exome data of hypertensive disorder 
Rank Position Gene Chr MAF1 OR1 W-test p-value 
1 64122856-64127883 
MACROD1/
LRP16 11 0.0010 3.84 6.1×10
-7 
2 149520895-149521591 -- 7 0.0012 3.09 5.2×10
-6 
3 54947030-54947395 NLRP7 19 0.0027 2.23 8.3×10
-6 
4 5809248-5809272 -- 11 0.0007 1.92 9.3×10
-6 
5 40843119-40843343 -- 17 0.0004 8.64 9.9×10
-6 
6 115091763-115091808 -- 13 0.0035 0.31 1.1×10
-5 
7 91732176-91746400 -- 7 0.0006 4.44 2.0×10
-5 
8 67103877-67109739 HELZ 17 0.0003 14.8 3.0×10
-5 
9 141619479-141635585 AGK 7 0.0015 2.55 3.6×10
-5 
10 141618669-141619479 AGK 7 0.0012 2.80 3.9×10
-5 
11 6328839-6413690 -- 9 0.0017 2.22 4.1×10
-5 
12 40268764-40290931 PAK6 15 0.0022 2.14 5.0×10
-5 
13 58102391-58111521 ZSCAN18 19 0.0006 4.20 5.2×10
-5 
14 41113238-41131622 KRTAP9-7 17 0.0014 2.52 5.5×10
-5 
15 7794026-7797451 -- 17 0.0010 2.63 6.6×10
-5 
16 2435288-2435470 -- 11 0.0011 2.75 9.3×10
-5 
17 6341489-6411783 
APBB1;SM
PD1 11 0.0007 3.00 9.9×10
-5 
1 MAF: average minor allele frequency in the collapsing region; OR: odds ratio for minor allele of the collapsed 
marker. 
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